290 related articles for article (PubMed ID: 14728049)
21. Metabolic management of ischemic heart disease: clinical data with trimetazidine.
Desideri A; Celegon L
Am J Cardiol; 1998 Sep; 82(5A):50K-53K. PubMed ID: 9737486
[TBL] [Abstract][Full Text] [Related]
22. Chronic angina: new medical options for treatment.
McCullough PA
Rev Cardiovasc Med; 2005; 6(3):152-61. PubMed ID: 16195688
[TBL] [Abstract][Full Text] [Related]
23. Protective effects of ranolazine, a novel anti-ischemic drug, on the hydrogen peroxide-induced derangements in isolated, perfused rat heart: comparison with dichloroacetate.
Matsumura H; Hara A; Hashizume H; Maruyama K; Abiko Y
Jpn J Pharmacol; 1998 May; 77(1):31-9. PubMed ID: 9639058
[TBL] [Abstract][Full Text] [Related]
24. Enhanced preservation of acutely ischemic myocardium using glucose-insulin-potassium solutions.
Lazar HL
J Card Surg; 1994 May; 9(3 Suppl):474-8. PubMed ID: 8069039
[TBL] [Abstract][Full Text] [Related]
25. Effects of ranolazine on ischemic threshold, coronary sinus blood flow, and myocardial metabolism in coronary artery disease.
Bagger JP; Bøtker HE; Thomassen A; Nielsen TT
Cardiovasc Drugs Ther; 1997 Jul; 11(3):479-84. PubMed ID: 9310277
[TBL] [Abstract][Full Text] [Related]
26. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
[TBL] [Abstract][Full Text] [Related]
27. The use of ranolazine in cardiovascular disease.
Schofield RS; Hill JA
Expert Opin Investig Drugs; 2002 Jan; 11(1):117-23. PubMed ID: 11772326
[TBL] [Abstract][Full Text] [Related]
28. Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders.
Bhandari B; Subramanian L
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):35-9. PubMed ID: 18221101
[TBL] [Abstract][Full Text] [Related]
29. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
Stanley WC; Marzilli M
Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
[TBL] [Abstract][Full Text] [Related]
30. A shift in myocardial substrate, improved endothelial function, and diminished sympathetic activity may contribute to the anti-anginal impact of very-low-fat diets.
McCarty MF
Med Hypotheses; 2004; 62(1):62-71. PubMed ID: 14729006
[TBL] [Abstract][Full Text] [Related]
31. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
[TBL] [Abstract][Full Text] [Related]
32. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
33. Metabolic modulation of myocardial ischemia.
Jani S; Bergmann SR
Curr Cardiol Rep; 2006 Mar; 8(2):123-30. PubMed ID: 16524539
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36).
Mega JL; Hochman JS; Scirica BM; Murphy SA; Sloan S; McCabe CH; Merlini P; Morrow DA
Circulation; 2010 Apr; 121(16):1809-17. PubMed ID: 20385930
[TBL] [Abstract][Full Text] [Related]
35. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
36. Demand-induced ischemia in volume expanded isolated rat heart; the effect of dichloroacetate and trimetazidine.
Skierczynska A; Beresewicz A
J Physiol Pharmacol; 2010 Apr; 61(2):153-62. PubMed ID: 20436215
[TBL] [Abstract][Full Text] [Related]
37. Ranolazine: a new approach to management of patients with angina.
Tafreshi MJ; Fisher E
Ann Pharmacother; 2006 Apr; 40(4):689-93. PubMed ID: 16595572
[TBL] [Abstract][Full Text] [Related]
38. Ranolazine: a novel metabolic modulator for the treatment of angina.
McCormack JG; Stanley WC; Wolff AA
Gen Pharmacol; 1998 May; 30(5):639-45. PubMed ID: 9559312
[TBL] [Abstract][Full Text] [Related]
39. Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation.
Stanley WC; Sabbah HN
Heart Fail Rev; 2005 Dec; 10(4):275-9. PubMed ID: 16583175
[No Abstract] [Full Text] [Related]
40. Modulation of myocardial energetics: An important category of agents in the multimodal treatment of coronary artery disease and heart failure.
Dalal JJ; Mishra S
Indian Heart J; 2017; 69(3):393-401. PubMed ID: 28648439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
